BACKGROUND: Penetrance for breast cancer, ovarian cancer, or both in carriers of BRCA1/BRCA2 mutations is disproportionately high. Sex hormone dysregulation and altered end-organ hormone sensitivity might explain this organ-specific penetrance. We sought to identify differences in hormone regulation between carriers of BRCA1/2 and women who are negative for BRCA1/2 mutations. METHODS: We assessed endometrial thickness for each menstrual cycle day (as an index of hormone regulation) in 393 scans from 228 women in the UK Familial Ovarian Cancer Screening Study (UK FOCSS) known to carry either mutation and 1573 scans from 754 women known to be negative for the mutations. To quantify differences in endometrial thickness we focused on days 10-14 and days 21-26, and calculated the area under the curve. We then compared serum oestradiol and progesterone titres during these days of the menstrual cycle in the same groups. Follicular and luteal oestradiol and progesterone serum titres were grouped into quartiles and odds ratios were calculated with logistic regression. FINDINGS: Follicular phase endometrial thickness of carriers of the mutations adjusted for age and day of the menstrual cycle was higher (odds ratio [OR] 1·11, 95% CI 1·03-1·20; p=0·0063) and luteal phase endometrial thickness lower (0·90, 0·83-0·98; p=0·027) than for women negative for the mutations. Median luteal phase titres of progesterone were 121% higher (p=0·00037) in carriers than in women negative for the mutations, and for oestradiol were 33% higher (p=0·007)-ie, 59% of carriers had concentrations of serum progesterone that would have been in the top quartile of concentrations in the control group (OR 8·0, 95% CI 2·1-52·57; p=0·008). INTERPRETATION: Carriers of BRCA1/BRCA2 mutations are exposed to higher titres of oestradiol and progesterone-known risk-factors for breast cancer. Higher titres of oestradiol in carriers are compatible with this hormone having a role in ovarian carcinogenesis in such women. Our findings could not be explained by differential contraceptive pill use.
BACKGROUND: Penetrance for breast cancer, ovarian cancer, or both in carriers of BRCA1/BRCA2 mutations is disproportionately high. Sex hormone dysregulation and altered end-organ hormone sensitivity might explain this organ-specific penetrance. We sought to identify differences in hormone regulation between carriers of BRCA1/2 and women who are negative for BRCA1/2 mutations. METHODS: We assessed endometrial thickness for each menstrual cycle day (as an index of hormone regulation) in 393 scans from 228 women in the UK Familial Ovarian Cancer Screening Study (UK FOCSS) known to carry either mutation and 1573 scans from 754 women known to be negative for the mutations. To quantify differences in endometrial thickness we focused on days 10-14 and days 21-26, and calculated the area under the curve. We then compared serum oestradiol and progesterone titres during these days of the menstrual cycle in the same groups. Follicular and luteal oestradiol and progesterone serum titres were grouped into quartiles and odds ratios were calculated with logistic regression. FINDINGS: Follicular phase endometrial thickness of carriers of the mutations adjusted for age and day of the menstrual cycle was higher (odds ratio [OR] 1·11, 95% CI 1·03-1·20; p=0·0063) and luteal phase endometrial thickness lower (0·90, 0·83-0·98; p=0·027) than for women negative for the mutations. Median luteal phase titres of progesterone were 121% higher (p=0·00037) in carriers than in women negative for the mutations, and for oestradiol were 33% higher (p=0·007)-ie, 59% of carriers had concentrations of serum progesterone that would have been in the top quartile of concentrations in the control group (OR 8·0, 95% CI 2·1-52·57; p=0·008). INTERPRETATION: Carriers of BRCA1/BRCA2 mutations are exposed to higher titres of oestradiol and progesterone-known risk-factors for breast cancer. Higher titres of oestradiol in carriers are compatible with this hormone having a role in ovarian carcinogenesis in such women. Our findings could not be explained by differential contraceptive pill use.
Authors: Olga Kim; Eun Young Park; Sun Young Kwon; Sojin Shin; Robert E Emerson; Yong-Hyun Shin; Francesco J DeMayo; John P Lydon; Donna M Coffey; Shannon M Hawkins; Lawrence A Quilliam; Dong-Joo Cheon; Facundo M Fernández; Kenneth P Nephew; Adam R Karpf; Martin Widschwendter; Anil K Sood; Robert C Bast; Andrew K Godwin; Kathy D Miller; Chi-Heum Cho; Jaeyeon Kim Journal: Proc Natl Acad Sci U S A Date: 2020-12-01 Impact factor: 11.205
Authors: Yakir Segev; Barry Rosen; Jan Lubinski; Jacek Gronwald; Henry T Lynch; Pal Moller; Charmaine Kim-Sing; Parviz Ghadirian; Beth Karlan; Charis Eng; Dawna Gilchrist; Susan L Neuhausen; Andrea Eisen; Eitan Friedman; David Euhus; Sun Ping; Steven A Narod Journal: Fam Cancer Date: 2015-09 Impact factor: 2.375
Authors: Caroline H Diep; Andrea R Daniel; Laura J Mauro; Todd P Knutson; Carol A Lange Journal: J Mol Endocrinol Date: 2015-01-13 Impact factor: 5.098
Authors: H N Hilton; L J Patterson McDonald; N Santucci; F R van der Bent; A Silvestri; J D Graham; C L Clarke Journal: J Mammary Gland Biol Neoplasia Date: 2019-05-18 Impact factor: 2.673
Authors: Emma Nolan; François Vaillant; Daniel Branstetter; Bhupinder Pal; Göknur Giner; Lachlan Whitehead; Sheau W Lok; Gregory B Mann; Kathy Rohrbach; Li-Ya Huang; Rosalia Soriano; Gordon K Smyth; William C Dougall; Jane E Visvader; Geoffrey J Lindeman Journal: Nat Med Date: 2016-06-20 Impact factor: 53.440
Authors: Martin Widschwendter; Allison Jones; Iona Evans; Daniel Reisel; Joakim Dillner; Karin Sundström; Ewout W Steyerberg; Yvonne Vergouwe; Odette Wegwarth; Felix G Rebitschek; Uwe Siebert; Gaby Sroczynski; Inez D de Beaufort; Ineke Bolt; David Cibula; Michal Zikan; Line Bjørge; Nicoletta Colombo; Nadia Harbeck; Frank Dudbridge; Anne-Marie Tasse; Bartha M Knoppers; Yann Joly; Andrew E Teschendorff; Nora Pashayan Journal: Nat Rev Clin Oncol Date: 2018-02-27 Impact factor: 66.675
Authors: Nikolaos Svoronos; Alfredo Perales-Puchalt; Michael J Allegrezza; Melanie R Rutkowski; Kyle K Payne; Amelia J Tesone; Jenny M Nguyen; Tyler J Curiel; Mark G Cadungog; Sunil Singhal; Evgeniy B Eruslanov; Paul Zhang; Julia Tchou; Rugang Zhang; Jose R Conejo-Garcia Journal: Cancer Discov Date: 2016-09-30 Impact factor: 39.397